Advertisement

Picture [iito] Fighting Customers 650x80px
Organisation › Details

Minoryx Therapeutics S.L.

Minoryx is a clinical stage biotech company piloting the development of new therapies for X-ALD and other rare diseases of genetic origin with a high unmet medical need. The company’s lead program is MIN-102, which may be effective in multiple CNS indications beyond X-ALD. The Minoryx team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma. The company is backed by a syndicate of experienced investors, has support from a network of other organizations and has operations in Spain and Belgium. Minoryx was founded in 2011 and has raised a total of €50M. *

 

Period Start 2011-01-01 established
  Group Minoryx (Group)
Products Industry DRUGS, ORPHAN
  Industry 2 MIN-102 (Minoryx)
Person Person Martinell, Marc (Minoryx Therapeutics SL 201404 CEO + Co-Founder)
     
Region Region Barcelona
  Country Spain (Espańa)
  Street 32 Av. Ernest Lluch
TecnoCampus MAtaró-Maresme, TCM2
  City 08302 Mataró (Barcelona)
  Tel +34-93-702-1975
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
     
    * Document for ďż˝About Sectionďż˝: Minoryx Therapeutics S.L.. (1/15/19). "Press Release: Minoryx Therapeutics Extends Its Activities in Belgium". Mataró, Barcelona & Charleroi.
     
   
Record changed: 2019-05-30

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Minoryx (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top